Vertex Pharmaceuticals (VRTX) Competitors $452.16 +6.96 (+1.56%) Closing price 07/1/2025 04:00 PM EasternExtended Trading$453.20 +1.03 (+0.23%) As of 08:58 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock VRTX vs. AMGN, GILD, REGN, ALNY, BIIB, INCY, UTHR, NBIX, EXEL, and BMRNShould you be buying Vertex Pharmaceuticals stock or one of its competitors? The main competitors of Vertex Pharmaceuticals include Amgen (AMGN), Gilead Sciences (GILD), Regeneron Pharmaceuticals (REGN), Alnylam Pharmaceuticals (ALNY), Biogen (BIIB), Incyte (INCY), United Therapeutics (UTHR), Neurocrine Biosciences (NBIX), Exelixis (EXEL), and BioMarin Pharmaceutical (BMRN). These companies are all part of the "biotechnology" industry. Vertex Pharmaceuticals vs. Its Competitors Amgen Gilead Sciences Regeneron Pharmaceuticals Alnylam Pharmaceuticals Biogen Incyte United Therapeutics Neurocrine Biosciences Exelixis BioMarin Pharmaceutical Amgen (NASDAQ:AMGN) and Vertex Pharmaceuticals (NASDAQ:VRTX) are both large-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, valuation, analyst recommendations, institutional ownership, profitability, media sentiment, dividends and earnings. Is AMGN or VRTX more profitable? Amgen has a net margin of 17.39% compared to Vertex Pharmaceuticals' net margin of -8.91%. Amgen's return on equity of 176.11% beat Vertex Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Amgen17.39% 176.11% 12.39% Vertex Pharmaceuticals -8.91%-3.36%-2.42% Do analysts prefer AMGN or VRTX? Amgen currently has a consensus target price of $307.82, indicating a potential upside of 5.95%. Vertex Pharmaceuticals has a consensus target price of $511.62, indicating a potential upside of 13.15%. Given Vertex Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Vertex Pharmaceuticals is more favorable than Amgen.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Amgen 2 Sell rating(s) 12 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 2.35Vertex Pharmaceuticals 0 Sell rating(s) 14 Hold rating(s) 13 Buy rating(s) 1 Strong Buy rating(s) 2.54 Which has stronger earnings & valuation, AMGN or VRTX? Amgen has higher revenue and earnings than Vertex Pharmaceuticals. Vertex Pharmaceuticals is trading at a lower price-to-earnings ratio than Amgen, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAmgen$33.42B4.67$4.09B$10.9626.51Vertex Pharmaceuticals$11.02B10.54-$535.60M-$3.92-115.35 Does the media refer more to AMGN or VRTX? In the previous week, Amgen had 14 more articles in the media than Vertex Pharmaceuticals. MarketBeat recorded 65 mentions for Amgen and 51 mentions for Vertex Pharmaceuticals. Vertex Pharmaceuticals' average media sentiment score of 1.12 beat Amgen's score of 0.99 indicating that Vertex Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Amgen 47 Very Positive mention(s) 1 Positive mention(s) 10 Neutral mention(s) 2 Negative mention(s) 3 Very Negative mention(s) Positive Vertex Pharmaceuticals 32 Very Positive mention(s) 0 Positive mention(s) 12 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do insiders and institutionals believe in AMGN or VRTX? 76.5% of Amgen shares are owned by institutional investors. Comparatively, 91.0% of Vertex Pharmaceuticals shares are owned by institutional investors. 0.7% of Amgen shares are owned by insiders. Comparatively, 0.2% of Vertex Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Which has more risk & volatility, AMGN or VRTX? Amgen has a beta of 0.49, meaning that its stock price is 51% less volatile than the S&P 500. Comparatively, Vertex Pharmaceuticals has a beta of 0.41, meaning that its stock price is 59% less volatile than the S&P 500. SummaryAmgen beats Vertex Pharmaceuticals on 10 of the 16 factors compared between the two stocks. Get Vertex Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for VRTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding VRTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VRTX vs. The Competition Export to ExcelMetricVertex PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$114.33B$2.85B$5.48B$8.94BDividend YieldN/A2.69%5.38%4.12%P/E Ratio-115.3521.1726.2219.74Price / Sales10.54262.85394.92109.12Price / CashN/A41.8936.4957.06Price / Book7.107.237.915.37Net Income-$535.60M-$55.05M$3.15B$248.34M7 Day Performance1.42%-0.60%0.75%1.67%1 Month Performance1.51%3.77%3.46%4.56%1 Year Performance-4.56%2.20%34.60%18.42% Vertex Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VRTXVertex Pharmaceuticals4.7266 of 5 stars$452.16+1.6%$511.62+13.2%-4.1%$114.33B$11.02B-115.356,100Positive NewsAMGNAmgen4.3174 of 5 stars$273.01-5.6%$309.22+13.3%-6.6%$146.97B$33.42B24.9428,000GILDGilead Sciences4.843 of 5 stars$106.05-2.3%$110.55+4.2%+62.8%$131.77B$28.75B22.3017,600Positive NewsInsider TradeREGNRegeneron Pharmaceuticals4.9403 of 5 stars$511.30+0.3%$836.48+63.6%-49.4%$55.16B$14.20B13.0115,106Analyst DowngradeALNYAlnylam Pharmaceuticals4.2888 of 5 stars$312.99+1.1%$319.58+2.1%+32.4%$40.82B$2.25B-149.602,230Positive NewsAnalyst ForecastBIIBBiogen4.9742 of 5 stars$124.68-1.9%$188.19+50.9%-43.9%$18.21B$9.68B12.277,605INCYIncyte4.3669 of 5 stars$67.28-1.7%$74.53+10.8%+12.9%$13.01B$4.41B210.112,617UTHRUnited Therapeutics4.9941 of 5 stars$286.48-1.5%$393.08+37.2%-8.8%$12.89B$2.88B11.401,305Positive NewsAnalyst ForecastNBIXNeurocrine Biosciences4.9388 of 5 stars$125.73-0.7%$162.00+28.9%-8.6%$12.43B$2.36B42.581,800Positive NewsEXELExelixis4.7384 of 5 stars$43.40+7.5%$41.00-5.5%+96.0%$11.82B$2.17B19.711,147Positive NewsAnalyst ForecastGap UpHigh Trading VolumeBMRNBioMarin Pharmaceutical4.9455 of 5 stars$53.99-1.8%$93.45+73.1%-31.6%$10.34B$2.95B20.043,040 Related Companies and Tools Related Companies Amgen Alternatives Gilead Sciences Alternatives Regeneron Pharmaceuticals Alternatives Alnylam Pharmaceuticals Alternatives Biogen Alternatives Incyte Alternatives United Therapeutics Alternatives Neurocrine Biosciences Alternatives Exelixis Alternatives BioMarin Pharmaceutical Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:VRTX) was last updated on 7/2/2025 by MarketBeat.com Staff From Our PartnersWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | Sponsored379 passengers walked away from thisElon Musk just wrote a $51 million check to back this material’s next phase… Because it’s not just saving l...True Market Insiders | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredForget Nvidia, This “Ghost Town” Company Holds the Key to the AI BoomCold War Discovery Could Unlock $100 Trillion in Wealth Jeff recently traveled to an American ghost town to...Brownstone Research | SponsoredIsrael-Iran WAR Could Destroy Trump's PresidencyThe missiles are already flying. Israel and Iran are now in direct military conflict — and this couldn't ha...American Alternative | SponsoredCrypto Is Pumping Again – Now Comes the Real OpportunityThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredThe #1 AI Energy StockNearly $600 billion is projected to be spent on AI data centers this year. That's because the ones being bu...Weiss Ratings | SponsoredTrump set to Boost Social Security Checks by 400%?If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vertex Pharmaceuticals Incorporated Please log in to your account or sign up in order to add this asset to your watchlist. Share Vertex Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free VRTX Stock Alerts